SHANGHAI – Epimab Biotherapeutics Inc., of Shanghai, inked its first licensing deal for its bispecific antibody platform technology to one of China's rising biopharma stars, Innovent Biologics Inc., of Suzhou. Epimab's technology, called Fabs-In-Tandem Immunoglobulin (FIT-Ig), approaches the creation of new bispecific antibodies making use of existing monoclonal antibodies (MAbs) with proven biology.
SHANGHAI – Dozens of Chinese biopharmas have entered the CAR T race, but Shanghai-based Innovative Cellular Therapeutics Co. Ltd., (ICT), also known as Sidansai in Chinese, is angling to be the front-runner.
SHANGHAI – Sorrento Therapeutics Inc., of San Diego, reported that STI-004 proved to be safe and efficacious in both adult and adolescent patients suffering from allergic asthma when compared to placebo, successfully completing a combined phase II/III study in China.
SHANGHAI – Established in 2005, Beike Biotechnology Co. Ltd., of Shenzhen, is one of China’s pioneering stem cell providers and until just a few years ago was very active at treating patients with stem cells. But when the rules changed in 2012 forbidding charging patients for stem cell treatments, Beike had to do some strategic business model retooling.
SUZHOU, China – At the Chinabio Partnering Forum, a panel of leading Chinese biopharma founders and executives discussed the future of immuno-oncology in China to a packed room in Suzhou, a biotech hub a short distance from Shanghai. The speakers were cautiously optimistic about China’s future in this hot new category of cancer treatment, artfully skirting around direct mention of the government’s recent ban on immunotherapy following a scandal involving a patient who died after receiving DC-CIK treatment.
SHANGHAI – Dozens of Chinese biopharmas have entered the CAR T race, but Shanghai-based Innovative Cellular Therapeutics Co. Ltd. (ICT), also known as Sidansai in Chinese, is angling to be the front-runner.
SHANGHAI – Established in 2005, Beike Biotechnology Co. Ltd., of Shenzhen, is one of China’s pioneering stem cell providers and until just a few years ago was very active at treating patients with stem cells. But when the rules changed in 2012 forbidding charging patients for stem cell treatments, Beike had to do some strategic business model retooling.
SHANGHAI – Sorrento Therapeutics Inc., of San Diego, reported that STI-004 proved to be safe and efficacious in both adult and adolescent patients suffering from allergic asthma when compared to placebo, successfully completing a combined phase II/III study in China.
SUZHOU, China – At the Chinabio Partnering Forum, a panel of leading Chinese biopharma founders and executives discussed the future of immuno-oncology in China to a packed room in Suzhou, a biotech hub a short distance from Shanghai. The speakers were cautiously optimistic about China's future in this hot new category of cancer treatment, artfully skirting around direct mention of the government's recent ban on immunotherapy following a scandal involving a patient who died after receiving DC-CIK treatment. (See BioWorld Today, May 10, 2016.)
SUZHOU, China – China's economy is evolving rapidly and the new normal of slower growth has arrived. But don't tell the folks in China's life sciences industry, one of the few bright spots in an otherwise messy time of economic transition. The sector enjoyed what Greg Scott, founder of Chinabio LLC calls "explosive growth" last year.
